Antenatal magnesium individual participant data international collaboration: Assessing the benefits for babies using the best level of evidence (AMICABLE)

Systematic Reviews

Volumn 1, Issue 1, 2012, Pages

  Crowther, C A ^a   Middleton, P F ^a   Askie, L M ^b   Doyle, L W ^c   Bubner, T K ^a   Voysey, M ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cerebral palsy; Individual patient data; Magnesium sulphate; Meta analysis; Preterm birth

Indexed keywords

MAGNESIUM SULFATE; PLACEBO; UTERUS SPASMOLYTIC AGENT;

ARTICLE; CEREBRAL PALSY; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; NAUSEA; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; PREMATURE LABOR; PRENATAL CARE; RISK FACTOR; SENSITIVITY ANALYSIS; VOMITING;

EID: 84876316286     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-1-21     Document Type: Article

References (51)

1. Doyle LW, Victorian Infant Collaborative S. Outcome at 5 years of age of children 23 to 27 weeks' gestation: Refining the prognosis. Pediatrics 2001, 108(1):134-141. 10.1542/peds.108.1.134, 11433066.
2. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008, 371(9608):261-269. 10.1016/S0140-6736(08)60136-1, 18207020.
3. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Munson ML. Births: final data for 2005. Natl Vital Stat Rep 2007, 56(6):1-103.
4. Laws P, Li Z, Sullivan EA. Australia's mothers and babies 2008, Perinatal statistics series no. 24. Cat. no. PER 50 2010, Canberra: AIHW.
5. Oxford Register of Early Childhood Impairment National Perinatal Epidemiology Unit 2001 Annual Report 2001, Oxford: Institue of Health Sciences, Oxford Register of Early Childhood Impairment.
6. Hutton JL, Cooke T, Pharoah POD. Life expectancy in children with cerebral palsy. Brit Med J 1994, 309(6952):431-435. 10.1136/bmj.309.6952.431, 2540919, 7920125.
7. Winter S, Autry A, Boyle C, Yeargin-Allsopp M. Trends in the prevalence of cerebral palsy in a population-based study. Pediatrics 2002, 110(6):1220-1225. 10.1542/peds.110.6.1220, 12456922.
8. Drummond PM, Colver AF. Analysis by gestational age of cerebral palsy in singleton births in north-east England 1970-94. Paediatr Perinat Epidemiol 2002, 16(2):172-180. 10.1046/j.1365-3016.2002.00408.x, 12060314.
9. Himpens E, Van den Broeck C, Oostra A, Calders P, Vanhaesebrouck P. Prevalence, type, distribution, and severity of cerebral palsy in relation to gestational age: a meta-analytic review. Dev Med Child Neurol 2008, 50(5):334-340. 10.1111/j.1469-8749.2008.02047.x, 18355333.
10. Glinianaia S, Rankin J, Selvin S, Nelson KB. Cerebral palsy rates by birth weight, gestation and severity in North of England, 1991-2000 singleton births. Arch Dis Child 2011, 96:180-185. 10.1136/adc.2010.183939, 21068077.
11. Stanley FJ, Watson L. Trends in Perinatal-Mortality and Cerebral-Palsy in Western-Australia, 1967 to 1985. Brit Med J 1992, 304(6843):1658-1663. 10.1136/bmj.304.6843.1658, 1882364, 1633518.
12. Sellier E, Surman G, Himmelmann K, Andersen G, Colver A, Krageloh-Mann I, De-la-Cruz J, Cans C. Trends in prevalence of cerebral palsy in children born with a birthweight of 2,500 g or over in Europe from 1980 to 1998. Eur J Epidemiol 2010, 25(9):635-642. 10.1007/s10654-010-9474-0, 20532622.
13. Kuban KC, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J Child Neurol 1992, 7(1):70-76. 10.1177/088307389200700113, 1552156.
14. Ancel PY, Livinec F, Larroque B, Marret S, Arnaud C, Pierrat V, Dehan M, N'Guyen S, Escande B, Burguet A, et al. Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE cohort study. Pediatrics 2006, 117(3):828-835. 10.1542/peds.2005-0091, 16510664.
15. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoriapapadopoulos M. Protective effect of MgSO4 infusion on nmda receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain Res 1994, 644(1):144-149. 10.1016/0006-8993(94)90357-3, 8032941.
16. Mildvan AS. Role of magnesium and other divalent cations in ATP-utilizing enzymes. Magnesium 1987, 6(1):28-33.
17. McIntosh TK, Vink R, Yamakami I, Faden AI. Magnesium protects against neurological deficit after brain injury. Brain Res 1989, 482(2):252-260. 10.1016/0006-8993(89)91188-8, 2784989.
18. Shogi T, Miyamoto A, Ishiguro S, Nishio A. Enhanced release of IL-1 beta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-Mg2+ medium. Magnesium Res 2003, 16(2):111-119.
19. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984, 307(5950):462-465. 10.1038/307462a0, 6320006.
20. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003, 3(1):9-20. 10.1007/s11910-003-0031-z, 12507405.
21. Rantonen TH, Gronlund JU, Jalonen JO, Ekblad UU, Kaapa PO, Kero PO, Valimaki IAT. Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Clin Physiol Funct Imaging 2002, 22(1):13-17.
22. Macdonald RL, Curry DJ, Aihara Y, Zhang ZD, Jahromi BS, Yassari R. Magnesium and experimental vasospasm. J Neurosurg 2004, 100(1):106-110. 10.3171/jns.2004.100.1.0106, 14743919.
23. Hallak M, Cotton DB. Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat. Am J Obstet Gynecol 1993, 169(2):427-431.
24. Nelson KB, Grether JK. Can magnesium sulphate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995, 95:1-1.
25. Wiswell TE, Graziani LJ, Caddell JL, Vecchione N, Stanley C, Spitzer AR. Maternally-administered magnesium sulfate (MgSO4) protects against early brain injury and long-term adverse neurodevelopmental outcomes in preterm infants: a prospective study. Pediatr Res 1996, 39(4):1502-1502.
26. Hauth JC, Goldenberg RL, Nelson KG, Dubard MB, Peralta MA, Gaudier FL. Reduction of cerebral palsy with maternal MgSO4 treatment in newborns weighing 500-1000 g. Am Obstetrics & Gynaecology 1995, 172(1 Pt 2):419.
27. Schendel DE, Berg CJ, YearginAllsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. Jama-J Am Med Assoc 1996, 276(22):1805-1810.
28. FineSmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, Kahn A, Fish I. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. Am J Perinat 1997, 14(5):303-307.
29. Grether JK, Hoogstrate J, Selvin S, Nelson KB. Magnesium sulfate tocolysis and risk of neonatal death. Am J Obstet Gynecol 1998, 178(1):1-6. 10.1016/S0002-9378(98)70617-9, 9465794.
30. Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B, MacPherson C, Thurnau GR. The effect of maternal magnesium sulfate treatment on neonatal morbidity in < = 1000-gram infants. Am J Perinat 1998, 15(11):635-641.
31. Paneth N, Jetton J, PintoMartin J, Susser M, Clark C, Gardiner J, Holzman C, Lorenz JM, Reuss ML. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. Pediatrics 1997, 99(5):E1. 10.1542/peds.99.5.e1, 9164797.
32. Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, Lusky A, Bental Y. Israel Neonatal Network: Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants. Arch Dis Child 2001, 85(1):F13-F17.
33. Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol 2000, 183(3):717-725. 10.1067/mob.2000.106581, 10992199.
34. O'Shea TM, Klinepeter KL, Meis PJ, Dillard RG. Intrauterine infection and the risk of cerebral palsy in very low-birthweight infants. Paediatr Perinat Epidemiol 1998, 12:(1):72-83.
35. Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology 1987, 67(5):806-808. 10.1097/00000542-198711000-00032, 2890318.
36. Levene M, Blennow M, Whitelaw A, Hanko E, Fellman V, Hartley R. Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. Arch Dis Child-Fetal 1995, 73(3):F174-F177.
37. Lipsitz PJ. The clinical effects of excess magnesium in the newborn. Pediatrics 1971, 47(3):501-509.
38. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009, (1):CD004661. DOI: 10.1002/14651858.CD004661.pub3.
39. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, Tomich PG. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002, 186(6):1111-1118. 10.1067/mob.2002.123544, 12066082.
40. Rouse DJ, Hirtz DG, Thom EA, et al. Magnesium sulfate for the prevention of cerebral palsy. New Engl J Med 2008, 359:895-905. 10.1056/NEJMoa0801187, 2803083, 18753646.
41. Crowther CA, Hiller JE, Doyle LW, Haslam RR, the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group Effect of magnesium sulfate given for neuroprotection before preterm birth-a randomized controlled trial. Jama-J Am Med Assoc 2003, 290(20):2669-2676. the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group.
42. Marret S, Marpeau L, Benichou J. Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics 2008, 121(1):225-226. 10.1542/peds.2007-2971, 18166581.
43. Duley L, Farrell B, Armstrong N, Spark P, Roberts B, Smyth R, Tivnan M, Laws A, Corfield N, Salter A, et al. The Magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. outcome for children at 18 months. Bjog-Int J Obstet Gy 2007, 114(3):289-299.
44. Chalmers I. The cochrane-collaboration - preparing, maintaining, and disseminating systematic reviews of the effects of health-care. Ann Ny Acad Sci 1993, 703:156-165. 10.1111/j.1749-6632.1993.tb26345.x, 8192293.
45. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002, 25(1):76-97. 10.1177/0163278702025001006, 11868447.
46. Cochrane Collaboration IPD Group Chapter 19 Reviews of individual patient data. Cochrane Handbook for Systematic Reviews of Interventions Version 500 [updated February 2008] 2008, USA: John Wiley & Sons Ltd, Higgins JPT, Green S, Cochrane Collaboration IPD Group.
47. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011, Higgins JPT, Green S., http://www.cochrane-handbook.org
48. Roberts CL, Lancaster PAL. Australian national birthweight percentiles by gestational age. Med J Australia 1999, 170(3):114-118.
49. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997, 39(4):214-223.
50. Bayley N. Bayley scales of infant development 1993, San Antonio: Psychological Corportation, 2.
51. WHO Multicentre Growth Reference Study Group WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr 2006, 450:76-85. WHO Multicentre Growth Reference Study Group.